<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03860688</url>
  </required_header>
  <id_info>
    <org_study_id>TED+GLC plasma 18-6296</org_study_id>
    <nct_id>NCT03860688</nct_id>
  </id_info>
  <brief_title>Effects of Oral Glucose and Teduglutide on Plasma Lipoproteins</brief_title>
  <acronym>TED+GLC plasma</acronym>
  <official_title>Investigating the Plasma Lipoprotein Response to a Single Subcutaneous Injection of Analogue Glucagon-like Peptide-2 and Oral Glucose in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some of the fat (triglyceride) from the food humans eat gets stored in the bowel. This
      triglyceride can then be released into the blood when another meal is consumed or in response
      to hormones. How the gut hormone glucagon-like peptide-2 (GLP-2) and glucose release the
      triglyceride from the gut is not known. The research team in this study is interested in
      finding out how teduglutide (a degradation resistant form of GLP-2) ang glucose, given
      together, release stored triglyceride from the gut by evaluating how blood lipoproteins
      respond to teduglutide in healthy individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The lipoprotein response will be performed in 15 healthy individuals recruited by newspaper
      advertisements. A member of the study team will explain the study in detail on visit 1, and
      if the individual is interested in participating, informed consent will be obtained and
      preliminary screening will occur. On visit 2 participants will receive a high fat liquid meal
      after an overnight fast. Hourly blood samples will be taken for 5 hours, followed by a
      subcutaneous teduglutide injection and simultaneous glucose drink. Following the injection
      and drink, blood samples will be taken every 15 minutes for the first hour and every 30
      minutes for the subsequent 3 hours.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>On visit 2, participants will receive teduglutide and glucose 5 hours after a liquid meal</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lipoprotein response to teduglutide and glucose</measure>
    <time_frame>8 hours</time_frame>
    <description>To quantify the plasma lipoprotein response to teduglutide (GLP-2 analogue) injection and oral glucose in healthy individuals</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>Teduglutide + glucose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TED + glucose</intervention_name>
    <description>Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose</description>
    <arm_group_label>Teduglutide + glucose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women, aged 18 to 60 years.

          -  Body mass index 20 to 27 kg/m2

        Exclusion Criteria:

          1. Patients with active inflammatory bowel disease

          2. Patients with pre-existing Celiac disease, exocrine pancreatic insufficiency or small
             bowel malabsorption

          3. Patients with active bowel malignancy

          4. Patients with diabetes mellitus or known/ suspected motility disorders of the gut

          5. Patients with decompensated liver disease

          6. Patients on ezetimibe or bile acid sequestrants

          7. Patients who are pregnant or breastfeeding.

          8. Patients with renal disease.

          9. Patients on benzodiazepine.

         10. Unstable cardiac or respiratory disease

         11. Any changes to medication in the preceding month

         12. Patients with hypersensitive to Revestive or any ingredient, active or a history of
             the drug within the last 5 years

         13. Patients with GI malignancy (GI tract, hepatobiliary, pancreatic)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brenda Hughes, RN</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>8886</phone_ext>
    <email>brenda.hughes@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gary Lewis, MD</last_name>
    <phone>416-340-4270</phone>
    <email>gary.lewis@uhn.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tornto General Hospital, UHN</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Hughes, RN</last_name>
      <phone>416-340-8886</phone>
      <email>brenda.hughes@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Gary F Lewis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>February 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intestinal lipoprotein</keyword>
  <keyword>Gut peptide</keyword>
  <keyword>Chylomicrons</keyword>
  <keyword>Glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

